Translational Breast Cancer Research最新文献

{"title":"A new pathological assessment method to assess residual lesions after neoadjuvant chemotherapy for breast cancer, residual disease in breast and nodes combined with Ki-67 (RDBN-K)","authors":"Ruoqi Han, Yanqi Ma, Zhi-kun Liu, Chun-xiao Li, Sainan Li, Xiang-lin Kong, Meng Han, Yueping Liu, C. Geng","doi":"10.21037/tbcr-21-39","DOIUrl":"https://doi.org/10.21037/tbcr-21-39","url":null,"abstract":"","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122838701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chinese expert consensus on coronavirus disease 2019 vaccination for breast cancer patients","authors":"J. Nie, Tao Wang, R. Xu, Jianbin Li, Yongmei Yin, Xiaojia Wang, C. Geng, Fu-Sheng Wang, Erwei Song, Zefei Jiang","doi":"10.21037/tbcr-21-31","DOIUrl":"https://doi.org/10.21037/tbcr-21-31","url":null,"abstract":"","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"2005 44","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132933396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study","authors":"Tao Wang, Pin Zhang, L. Di, Xiaojia Wang, Jun-lan Yang, Z. Tong, Jian Liu, Jifeng Feng, Donggeng Liu, Qitao Yu, Yunpeng Liu, Hao Yu, Zefei Jiang","doi":"10.21037/tbcr-21-42","DOIUrl":"https://doi.org/10.21037/tbcr-21-42","url":null,"abstract":"","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"305 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134180033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Round table discussion: strategies for the treatment of HER2-positive advanced breast cancer in the rising age of antibody-drug conjugates","authors":"Ying Yan, Qiao Li, Jianbin Li","doi":"10.21037/tbcr-21-45","DOIUrl":"https://doi.org/10.21037/tbcr-21-45","url":null,"abstract":"","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120951143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance","authors":"C. Campbell, J. Mathew, I. Ellis, I. Bradbury, S. Borgquist, K. Elebro, A. Green, P. Finlay, J. Gee, J. Robertson","doi":"10.21037/tbcr-20-31","DOIUrl":"https://doi.org/10.21037/tbcr-20-31","url":null,"abstract":"Background: It remains clinically important to identify ER positive breast cancers likely to respond to tamoxifen (TAM) and so we aimed to select a group of biomarkers able to predict with ER & lower Ki-67 proved the most predictive markers for better outcome (TTP & TTD and/or CBR) following TAM treatment. central biomarkers RPPA","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117054382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancer patients with low estrogen receptor expression gain no significant survival benefit from endocrine therapy: a real-world study from China","authors":"Shuqian Wang, Jianbin Li, Zefei Jiang, Yongmei Yin, Yunjiang Liu, haibo wang, Y. Teng, Li Ma, Yuhua Song, P. Fu","doi":"10.21037/tbcr-20-24","DOIUrl":"https://doi.org/10.21037/tbcr-20-24","url":null,"abstract":"Background: The efficacy of endocrine therapy in breast cancer patients expressing low levels (1–9%) of estrogen receptor (ER) is controversial, and there is limited clinical information about these patients. Methods: Patients diagnosed with stage I to III primary invasive breast cancer with low ER expression between January 2008 and December 2016 from six breast centers in China were recruited for this study. Results: Among the total of 17,216 patients, 457 (2.7%) showed low ER expression. Of the 457 patients, 56.9%, 61.6%, and 71.6% of tumors were human epidermal growth factor 2 (HER2) positive, progesterone receptor (PR) negative, and Ki-67 status >20%, respectively. Of these 457 patients, 112 patients received neoadjuvant chemotherapy, while 276 received adjuvant chemotherapy, and 170 patients received endocrine therapy. The total pathological complete response (pCR) rate was 26.8%. The rate of patients who received endocrine therapy was center and time-dependent. ER expression, PR expression, Ki-67 status, and lymphovascular invasion (LVI) were associated with endocrine therapy decision-making using univariate logistic regression analysis. However, the adjustment for other covariates revealed that only the ER was significantly associated with the rate of patients receiving endocrine therapy. Compared to patients <5% ER-positive tumors, patients with 5–9% ER-positive tumors were significantly more likely to receive endocrine therapy (OR, 2.882; 95% CI: 1.928–4.308; P<0.001). The median follow-up time was 30 months, and the five-year recurrence-free survival (RFS) rate was 85%. Younger age and positive lymph nodes were associated with worse RFS. The survival rate was not significantly different between patients who received and those patients who did not receive endocrine therapy. Conclusions: The 2010 ACSO/CAP recommendations increased in the proportion of patients with low ER expression receiving endocrine therapy. However, these patients do not appear to receive help from endocrine therapy.","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"338 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126949799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pyrotinib: a new promising targeted agent for human epidermal growth factor receptor 2-positive breast cancer","authors":"M. Perachino, L. Arecco, V. Martelli, M. Lambertini","doi":"10.21037/tbcr.2020-20-34","DOIUrl":"https://doi.org/10.21037/tbcr.2020-20-34","url":null,"abstract":"Approximately 20% of all new breast cancer cases are characterized by the positivity for the human epidermal growth factor receptor 2 (HER2) in terms of gene amplification or overexpression of its protein (1). Despite being characterized by an aggressive behavior and poorer prognosis, the advent of anti-HER2 targeted therapies has dramatically improved the survival of patients affected by this disease subtype over the last two decades (2). Nowadays, in the advanced setting, patients with HER2-positive breast cancer are those who are administered with more lines of treatment and with the expected longer survival outcomes as compared to patients affected by other subtypes (3,4). To further improve the outcomes of patients with HER2positive metastatic breast cancer and possibly increase the chances of cure even in the presence of advanced disease, developing new effective targeted treatment options remains a priority (5). The current standard of care in the first-line setting of HER2-positive metastatic breast cancer is represented by chemotherapy with a taxane as single agent in combination with dual anti-HER2 blockade including the monoclonal antibodies pertuzumab plus trastuzumab (6,7). This regimen has shown an extraordinary and unprecedented overall survival (OS) gain in this setting (8). Following treatment with trastuzumab plus a taxane, the antibody drug-conjugate trastuzumab emtansine (T-DM1) represents the current recommended approach (9), although more limited evidence on its performance exists in patients previously exposed also to pertuzumab (10). Based on current guidelines, the tyrosine kinase inhibitor (TKI) lapatinib in combination with capecitabine represents one of the available third-line treatment options (6,7). In recent years, several other TKIs have been developed for patients with HER2-positive metastatic breast cancer (Table 1) (11-22). Among the different TKIs, in addition to lapatinib, also neratinib and tucatinib have been recently approved by the Food and Drug Administration (FDA) thus becoming two new available targeted treatment options for patients with HER2-positive metastatic breast cancer (Figure 1). The NALA trial compared a combination of neratinib plus capecitabine versus lapatinib plus capecitabine in patients affected by HER2-positive metastatic breast cancer previously treated with at least two lines of therapy (11). The s tudy showed a s igni f icant improvement in progression-free survival (PFS) favoring neratinib [mean PFS 8.8 vs. 6.6 months; hazard ratio (HR) 0.76, 95% confidence interval (CI): 0.63–0.93, P=0.0059] without difference in OS (mean 24.0 vs. 22.2 months; HR 0.88, 95% CI: 0.72–1.07, P=0.2086) (11). Important results have more recently become available from the HER2CLIMB trial that investigated the addition of tucatinib to capecitabine and trastuzumab. A significant improvement in both PFS (median 7.8 vs. 5.6 months; HR 0.54, 95% CI: 0.42–0.71, P<0.001) and OS (21.9 vs. 17.4 months; HR 0.66, 9","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"96 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115692105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world study: from real-world data to real-world evidence","authors":"Y. Wen","doi":"10.21037/tbcr-20-19","DOIUrl":"https://doi.org/10.21037/tbcr-20-19","url":null,"abstract":"In recent years, real-world data (RWD) and real-world evidence (RWE) have rapidly become a focus area of medical research and attracted extensive attention from academia, industry and government. Given the high exposure of these topics, the concept of RWD and RWE have been fully discussed and well defined in many publications (1-3). Literally, it would not be difficult to understand that RWD is the raw materials based on which RWE was generated. However, in the world of scientific research, process matters. A poor research process could easily ruin the valuable study data and lead to inappropriate conclusions and misleading evidence. Therefore, in order to make the best use of RWD to generate the most convincing RWE, special attentions must to be paid to the study process. In order to have a more objective understanding about this process, this paper shares some facts of as well as thoughts about the process by asking four simple questions. Several terms have been used interchangeably to describe this process, such as real-world evidence study, real-world data study, real-world research and real-world study (4-7). Instead of discussing and distinguishing these terms or coining a new one, real-world study (RWS) would be used throughout this article.","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130720763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practice of surgical treatment of breast cancer in china during the novel coronavirus COVID-19 outbreak","authors":"Hongjin Liu, Ling Xu, Yin-hua Liu, Jing-ming Ye","doi":"10.21037/tbcr-20-18","DOIUrl":"https://doi.org/10.21037/tbcr-20-18","url":null,"abstract":"The corona virus disease 2019 (COVID-19) outbreak poses unprecedented challenges for patients, clinicians and healthcare systems. As hospital resources and staff become more limited during the COVID-19 outbreak, clinicians are facing many problems in managing breast cancer (BC) patients, such as how to define which patients require more urgent care and which patients can wait for treatment, how to manage the wards, operating rooms and staff, how to perform the postoperative management and follow-up of postoperative patients, etc. This article summarizes the experiences of surgical treatment of BC in China during the COVID-19 outbreak. Meanwhile, we hope that this article can provide clinicians in other affected areas valuable information so they don’t have to enter the battlefield alone.","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"49 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121847729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of tumor heterogeneity at the molecular level: a case report of efficacy separation in metastatic breast cancer","authors":"Xiangyi Li, L. Bian, Fengrui Xu, Z. Qu, Fan Yang, Zefei Jiang","doi":"10.21037/tbcr-20-20","DOIUrl":"https://doi.org/10.21037/tbcr-20-20","url":null,"abstract":": Although breast cancer frequently metastasizes to the lungs, rarely breast cancer patients develop separation of the efficacy of different lesions in pulmonary metastases. Differentiation at genetic level between drug-resistant lesion and sensitive lesion may be very challenging but is essential for prognostic and therapeutic considerations. In the present case study of a 51-year-old patient who had recurrent disease with pulmonary metastases after a left modified radical mastectomy three years later. Her two lesions of left pulmonary metastatic disease had a separation of therapeutic effects by treatment with albumin paclitaxel in imaging. Histological and immunohistochemical finds suggested that these two lesions were not inconsistent. A total of 230 cancer predisposition genes were analyzed by next generation sequencing and 25 gene mutations were detected, including MUTYH , ALK , MSH6 , PIK3CA , TP53 , AR , BRAF , EGFR , EPHX1 , NRAS , RET , STK11 , FBXW7 , CD274 and MET were identified. The unique gene mutations of drug-resistant lesion were: CD274 , MET , EPHX1 , FBXW7 and TP53 . The mutation genes specific to sensitive lesions were: KDR , FGFR4 , CDH1 , FGFR2 , PTEN and SLC22A4 . Which indicated that there was a difference between the two lesions at the genetic level. Even if there are efficacy separation in different metastatic lesions of the same organ in the same patient, the underlying cause may be genetic differences. Moreover, gene sequencing is also a supplement to traditional pathology. In summary, our results support the usage of next generation sequencing as a supplementary tool, assisting in revealing genetic heterogeneity. This is the first case report, to our knowledge, of difference between lesions in lung metastases, suggesting the existence of a patient with distant metastases who would be different for therapy as a result of carrying heterogeneity.","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"119 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122903105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}